Biotechnology indicators by company size.

• Select values to consult
  • Indicator type

    Values that contain

    Number of companies carrying out R&D in Biotechnology % Companies by type of biotechnology used: Genetic Code % Companies by type of biotechnology used: Functional Units % Companies by type of biotechnology used: Cell and Tissue Culture and Engineering % Companies by type of biotechnology used: Bioprocesses % Companies by type of biotechnology used: Subcellular Organisms % Companies by type of biotechnology used: Bioinformatics % Companies by type of biotechnology used: Nanobiotechnology % Companies by type of biotechnology used: Other Companies in which biotechnology activities are: Main and/or exclusive Companies in which biotechnology activities are: A secondary business line Companies in which biotechnology activities are: A necessary tool for production % Companies by final application areas of biotechnology use: Human Health % Companies by final application areas of biotechnology use: Animal Health and Aquaculture % Companies by final application areas of biotechnology use: Food Products % Companies by final application areas of biotechnology use: Agriculture and Forestry % Companies by final application areas of biotechnology use: Environment % Companies by final application areas of biotechnology use: Industry R&D personnel in Biotechnology (PP) R&D personnel in Biotechnology (PP): Research personnel R&D personnel in Biotechnology (PP): Technical and auxiliary personnel R&D personnel in Biotechnology (PP). Women R&D personnel in Biotechnology (PP). Women: Research personnel R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel R&D personnel in Biotechnology (FTE) R&D personnel in Biotechnology (FTE): Research personnel R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel R&D personnel in Biotechnology (FTE). Women R&D personnel in Biotechnology (FTE). Women: Research personnel R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel Expenditure on internal R&D in Biotechnology (thousands of euros) 1) By type of expenditure: Current expenditure 1.1) Labour expenditure of research personnel 1.2) Labour expenditure of technical and auxiliary personnel 1.3) Other current expenditure 2) By type of expenditure: Capital expenditure 2.1) Land and buildings 2.2) Equipment and tools 2.3) Acquisition of specific R&D software 2.4) Other R&D-specific IP products 1.1) By origin of funds: Own funds 1.2) By origin of funds: Funds from the Business sector 1.3) By origin of funds: Funds from the Public Administration sector 1.4) By origin of funds: Funds from the Higher Education sector 1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector 1.6) By origin of funds: Funds from the rest of the world Purchase of R&D services (external R&D) in Biotechnology (thousands of euros) Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information % Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources % Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain % Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets % Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels % Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception % Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements % Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost % Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting % Companies with international revenues related to biotechnology activities % Companies representing international revenues related to biotechnology activities % International revenues related to biotechnology activities distributed in: Revenues from the EU % International revenues related to biotechnology activities distributed in: Revenues from the rest of the world % International revenues related to biotechnology activities by classification: International trade in goods and services % International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain % International revenues related to biotechnology activities by classification: Subsidies from external sources % International revenues related to biotechnology activities by classification: Other

    Selected:67

    Total:67
  • Size of the company

    Values that contain

    Less than 250 employees 250 and more employees Total

    Selected:3

    Total:3
• Choose format of the table

  • 	Size of the company
    Indicator type	.	.	.
    	.	.	.
    	.	.	.

  • Decimals to show: By default 0 1
• Notes
  • 1) Data referring to all companies that carry out internal R&D in Biotechnology.
    2) ' .'= numeric data equal to zero not resulting from rounding
    3) FTE: Full-Time Equivalence

• Source:National Statistics Institute